Gainers
- LogicMark LGMK shares increased by 34.5% to $0.01 during Monday's regular session.
- CG Oncology CGON shares moved upwards by 32.81% to $29.71. The market value of their outstanding shares is at $2.2 billion.
- Zhengye Biotechnology ZYBT stock rose 32.18% to $13.8. The company's market cap stands at $654.0 million.
- iBio IBIO shares moved upwards by 30.56% to $1.2. The company's market cap stands at $11.8 million.
- Gelteq GELS shares increased by 24.21% to $2.36. The company's market cap stands at $22.2 million.
- Brainstorm Cell BCLI shares moved upwards by 24.0% to $1.21. The company's market cap stands at $6.8 million.
Losers
- Spruce Biosciences SPRB shares fell 26.2% to $0.1 during Monday's regular session. The company's market cap stands at $3.9 million.
- SILO Pharma SILO stock fell 22.6% to $0.89. The company's market cap stands at $3.9 million.
- Senti Biosciences SNTI shares decreased by 20.8% to $3.96. The market value of their outstanding shares is at $102.9 million.
- Abpro Hldgs ABP stock fell 18.94% to $0.26. The market value of their outstanding shares is at $13.4 million.
- Healthcare Triangle HCTI shares decreased by 18.74% to $0.15. The company's market cap stands at $6.7 million.
- Protara Therapeutics TARA stock declined by 18.52% to $3.52. The company's market cap stands at $129.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
ABPAbpro Holdings Inc
$0.20735.66%
Edge Rankings
Momentum
N/A
Growth
N/A
Quality
N/A
Value
7.55
Price Trend
Short
Medium
Long
BCLIBrainstorm Cell Therapeutics Inc
$0.8400-%
CGONCG Oncology Inc
$28.00-1.62%
GELSGelteq Ltd
$1.78-4.81%
HCTIHealthcare Triangle Inc
$0.0194-6.73%
IBIOiBio Inc
$0.7300-%
LGMKLogicMark Inc
Not Available-%
SILOSILO Pharma Inc
$0.64001.27%
SNTISenti Biosciences Inc
$1.94-3.48%
SPRBSpruce Biosciences Inc
$0.110040.0%
TARAProtara Therapeutics Inc
$3.08-1.91%
ZYBTZhengye Biotechnology Holding Ltd
$5.70-2.90%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.